PRISMA

PRISMA
Name	PRISMA
Developer	Cochrane Collaboration; Moher, David
Initial release	2009
Latest release	2020
Platform	Guidelines

PRISMA is an evidence-based reporting guideline designed to improve the transparency, completeness, and reproducibility of systematic reviews and meta-analyses. It provides authors, editors, and peer reviewers with a structured checklist and flow diagram to ensure essential items are reported in manuscripts. Developed through consensus among methodologists, clinicians, and journal editors, the guideline has been influential across biomedical, public health, and social science literatures.

Background and Purpose

PRISMA originated from concerns about inconsistent reporting in systematic reviews highlighted by researchers associated with Cochrane Collaboration, David Moher, and other methodologists active in initiatives such as the QUOROM Statement reform and the Oxford Centre for Evidence-Based Medicine. The purpose was to offer a standardized reporting framework akin to reporting standards like CONSORT for randomized trials and STROBE for observational studies. PRISMA aims to make review methods and results transparent so that readers can assess validity, replicate analyses, or update findings; stakeholders ranging from journal editors at The BMJ and The Lancet to guideline panels at National Institute for Health and Care Excellence rely on PRISMA-aligned reports for decision-making. The initiative drew attention from institutions including World Health Organization and National Institutes of Health which promote rigorous synthesis methods.

Development and Versions

The initial iteration evolved from the QUOROM Statement through consensus meetings attended by leaders from Cochrane Collaboration, International Committee of Medical Journal Editors, and journal editors from JAMA and Annals of Internal Medicine. The first widely used PRISMA statement was published in 2009 after systematic consultation with contributors from EQUATOR Network, Campbell Collaboration, and academic centers such as McMaster University and University of Oxford. A major update released in 2020 incorporated advances in methodology advocated by contributors from GRADE Working Group, Cochrane Methods Group, and evidence synthesis teams at Johns Hopkins University. The 2020 version expanded items to address new reporting needs and harmonize with initiatives by European Medicines Agency and regulatory stakeholders like U.S. Food and Drug Administration.

Reporting Items and Checklist

PRISMA provides a structured checklist of reporting items spanning title, abstract, introduction, methods, results, discussion, and other information. Items guide authors to report eligibility criteria, search strategies, data collection processes, risk-of-bias assessments, synthesis methods, and certainty of evidence evaluations—concepts informed by frameworks such as GRADE Working Group and tools like ROB 2 and ROBINS-I. The statement includes a flow diagram template documenting records identified, screened, assessed for eligibility, and included, a format familiar to readers of journals including PLOS Medicine and BMJ Open. PRISMA’s checklist also advises disclosure of registration in repositories such as PROSPERO and protocol publications in outlets like Systematic Reviews to enhance transparency and pre-specification.

Implementation and Use in Systematic Reviews

Journals and publishers implement PRISMA by requiring completed checklists at submission to editorial offices at Elsevier, Springer Nature, and Wiley. Review authors apply PRISMA during protocol development and manuscript preparation; guideline developers at bodies such as National Institute for Health and Care Excellence and Agency for Healthcare Research and Quality use PRISMA-conformant reviews when constructing recommendations. Educational programs in institutions like Harvard Medical School and University of Toronto incorporate PRISMA training in curricula for clinicians and researchers. Reporting compliance is often audited in methodological studies published in The BMJ, JAMA, and Cochrane Database of Systematic Reviews to monitor adherence across disciplines.

Extensions and Adaptations

Recognizing diverse review types, the PRISMA framework spawned extensions tailored for specific designs and data types. Notable extensions include PRISMA-P for protocols, PRISMA-ScR for scoping reviews, PRISMA-IPD for individual participant data meta-analyses, and PRISMA-S for search reporting; collaborators include experts linked to EQUATOR Network, Cochrane Methods Group, and specialty societies such as American Thoracic Society and European Society of Cardiology. Adaptations address network meta-analysis methods used by groups at Centre for Evidence-Based Medicine and reporting of harms emphasized by regulators like European Medicines Agency. These extensions often undergo separate consensus processes involving stakeholders from organizations such as PROSPERO and journals like Systematic Reviews.

Criticisms and Limitations

Critiques of PRISMA include concerns about checklist misuse as a box-ticking exercise by editorial offices at Elsevier and Springer Nature rather than genuine methodological appraisal, and the variable enforcement of items by journals including The Lancet and Nature Medicine. Methodologists from institutions such as University College London and McMaster University note that PRISMA addresses reporting quality but does not itself ensure methodological rigor of syntheses, a limitation also acknowledged in guidance from Cochrane Collaboration and GRADE Working Group. Other limitations involve applicability to non-health domains where stakeholders at United Nations-affiliated agencies or social science publishers may require adaptations, and challenges documenting complex living reviews promoted by groups at Johns Hopkins University and University of Edinburgh.

Category:Reporting guidelines